Redhill Biopharma Ltd.
RedHill Biopharma Ltd. focuses on gastrointestinal and infectious diseases. They develop and commercialize Talicia for H. pylori infection and Aemcolo for travelers diarrhea. Their pipeline includes five therapeutic candidates: opaganib, RHB-107, RHB-104, RHB-102, and RHB-204. These candidates are in clinical development for various indications. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Overview
Strengths
- The company has low debt. Net Debt to EBITDA Ratio is 0.32 and it is lower than the sector mean.
- The company has high returns. ROIC (100.00%) is higher than the sector mean (14.71%).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 100.0% |
| Net Debt/EBITDA | 0.3 |